Editing Coenzyme Q10 (section)

==Research==
A 2014 [[Cochrane review]] found insufficient evidence to make a conclusion about its use for the prevention of heart disease.<ref name="pmid25474484">{{cite journal | vauthors = Flowers N, Hartley L, Todkill D, Stranges S, Rees K | title = Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease | journal = The Cochrane Database of Systematic Reviews | volume = 2014 | issue = 12 | pages = CD010405 | date = 4 December 2014 | pmid = 25474484 | pmc = 9759150 | doi = 10.1002/14651858.CD010405.pub2 }}</ref> A 2016 Cochrane review concluded that CoQ<sub>10</sub> had no effect on [[blood pressure]].<ref name="pmid26935713">{{cite journal | vauthors = Ho MJ, Li EC, Wright JM | title = Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension | journal = The Cochrane Database of Systematic Reviews | volume = 2016 | issue = 3 | pages = CD007435 | date = March 2016 | pmid = 26935713 | pmc = 6486033 | doi = 10.1002/14651858.CD007435.pub3 }}</ref> A 2021 Cochrane review found "no convincing evidence to support or refute" the use of CoQ<sub>10</sub> for the treatment of heart failure.<ref name="pmid35608922">{{cite journal | vauthors = Al Saadi T, Assaf Y, Farwati M, Turkmani K, Al-Mouakeh A, Shebli B, Khoja M, Essali A, Madmani ME | title = Coenzyme Q10 for heart failure | journal = The Cochrane Database of Systematic Reviews | volume = 2021 | issue = 2 | pages = CD008684 | date = February 2021 | pmid = 35608922 | pmc = 8092430 | doi = 10.1002/14651858.CD008684.pub3 | collaboration = Cochrane Heart Group }}</ref>

A 2017 [[meta-analysis]] of people with heart failure taking 30–100&nbsp;mg/d of CoQ<sub>10</sub> found a 31% lower mortality and increased exercise capacity, with no significant difference in the endpoints of left heart ejection fraction.<ref name="pmid28738783">{{cite journal | vauthors = Lei L, Liu Y | title = Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials | journal = BMC Cardiovascular Disorders | volume = 17 | issue = 1 | pages = 196 | date = July 2017 | pmid = 28738783 | pmc = 5525208 | doi = 10.1186/s12872-017-0628-9 | doi-access = free }}{{Creative Commons text attribution notice|cc=by4|from this source=yes}}</ref> A 2021 meta-analysis found that coenzyme Q10 was associated with a 31% lower all-cause mortality in HF patients.<ref>{{Cite journal |last1=Khan |first1=Muhammad Shahzeb |last2=Khan |first2=Fiza |last3=Fonarow |first3=Gregg C. |last4=Sreenivasan |first4=Jayakumar |last5=Greene |first5=Stephen J. |last6=Khan |first6=Safi U. |last7=Usman |first7=Muhammad Shariq |last8=Vaduganathan |first8=Muthiah |last9=Fudim |first9=Marat |last10=Anker |first10=Stefan D. |last11=Butler |first11=Javed |date=June 2021 |title=Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map |url=https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2278 |journal=European Journal of Heart Failure |language=en |volume=23 |issue=9 |pages=1468–1476 |doi=10.1002/ejhf.2278 |pmid=34173307 |issn=1388-9842 |access-date=10 June 2024 |archive-date=2 January 2023 |archive-url=https://web.archive.org/web/20230102122936/https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2278 |url-status=live }}</ref> In a 2023 meta-analysis of older people, ubiquinone had evidence of a cardiovascular effect, but ubiquinol did not.<ref name="pmid37971634">{{cite journal | vauthors = Fladerer JP, Grollitsch S | title = Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality | journal = Current Cardiology Reports | volume = 25 | issue = 12 | pages = 1759–1767 | date = December 2023 | pmid = 37971634 | pmc = 10811087 | doi = 10.1007/s11886-023-01992-6 | doi-access = free }}</ref>

Although CoQ<sub>10</sub> has been studied as a potential remedy to treat purported muscle-related [[side effect]]s of [[statin]] medications, the results were mixed. Although a 2018 meta-analysis concluded that there was preliminary evidence for oral CoQ<sub>10</sub> reducing statin-associated muscle symptoms, including muscle pain, muscle weakness, muscle cramps, and muscle tiredness,<ref name="pmid30371340">{{cite journal | vauthors = Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ | title = Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials | journal = Journal of the American Heart Association | volume = 7 | issue = 19 | pages = e009835 | date = October 2018 | pmid = 30371340 | pmc = 6404871 | doi = 10.1161/JAHA.118.009835 }}{{Creative Commons text attribution notice|cc=by4|from this source=yes}}</ref> 2015<ref name="pmid25440725"/> and 2024<ref name="pmid36852817"/> meta-analysis found that CoQ<sub>10</sub> had no effect on statin myopathy.<ref name="pmid25440725">{{cite journal | vauthors = Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Lip GY, Dragan S, Mikhailidis DP | title = Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials | journal = Mayo Clinic Proceedings | volume = 90 | issue = 1 | pages = 24–34 | date = January 2015 | pmid = 25440725 | doi = 10.1016/j.mayocp.2014.08.021 | type = Systematic Review and Meta-Analysis }}</ref><ref name="pmid36852817"/>

CoQ<sub>10</sub> is studied as an adjunctive therapy to reduce inflammation in [[periodontitis]].<ref name="pmid37592831"/>